Phase 2 Head and Neck Cancer Trial, Recruiting NCT06935188 Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT06935188
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (any sex).
  • You have been diagnosed with squamous cell carcinoma of the head and neck that has been confirmed by a tissue biopsy, and the cancer has either come back after surgery, spread to other parts of the body, or cannot be removed with surgery — and it can be measured on a scan.
  • You have already received at least one round of a type of immunotherapy (called PD-1 therapy), your cancer has since grown or stopped responding, and this treatment ended at least 4 weeks before joining the trial with any side effects mostly resolved.
  • Your cancer has tested negative for the HPV virus (tested using a specific laboratory method).
  • You can provide a tumor tissue sample (either a stored sample from within the last 2 years or a fresh sample) for laboratory testing.
  • You are generally active and able to carry out daily activities with little or no restriction (confirm with trial site regarding the specific fitness scale used).
  • Your doctor expects you to live for at least 12 weeks.
  • Your blood counts, liver, kidneys, urine, blood sugar, lung function, and heart are all working well enough based on blood and other tests taken within 2 weeks before starting treatment (confirm with trial site for specific values).

Who may not be able to join:

  • You have previously been treated with cetuximab or similar drugs that target a protein called EGFR (either as an injection or a pill).
  • You are currently receiving any cancer treatment.
  • You have taken part in another clinical trial within the 4 weeks before starting this study.
  • You have received certain blood-boosting injections (such as G-CSF or erythropoietin) within 1 week before starting the study.
  • You have tested positive for HIV or syphilis.
  • You have active hepatitis B or hepatitis C, confirmed by specific blood tests.
  • You have a known allergy or sensitivity to the type of drug being used in this trial or its ingredients.
  • You have a large build-up of fluid in your lungs or abdomen that is causing symptoms and needs treatment.
  • You have an active lung condition such as interstitial lung disease, pneumonia, asthma, or obstructive lung disease, or a history of active tuberculosis.
  • You have any serious uncontrolled health problem, including severe infection, poorly controlled diabetes, significant heart problems, blood clots, recent stroke or heart attack, or certain heart procedures within the last 6 months (confirm with trial site for the full list).
  • You have previously had a stem cell transplant or organ transplant.
  • You have a history of drug or substance misuse that you are unable to stop, or a history of serious psychiatric illness.
  • You have had another type of cancer within the past 5 years.
  • Your doctor believes you are unlikely to follow the trial requirements or that participation would not be appropriate for another reason.
  • You have other serious medical conditions or abnormal test results that the trial doctor believes could put you at risk or affect the trial results (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yue He, the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Phone: 13916948812

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Registry
ClinicalTrials.gov
Start date
17 April 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression Free Survival Per RECIST 1.1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov